StockData
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc. (AVTX) stock

AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$6.70−0.43 (-6.03%)

Close on Nov 18, 2026Market cap $359.32MP/E –Yield –

Avalo Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Avalo Therapeutics's price to sales ratio was 118.3× on Apr 30, 2025, against 7.1× a year earlier. Over the last 5 years it ranged from 0.1× to 190.2×, with a median of 15.1×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Apr 30, 2025118.3×+30.5
2024Dec 31, 202487.7×+84.5
2023Dec 29, 20233.2×+0.5
2022Dec 30, 20222.7×−25.9
2021Dec 31, 202128.6×−5.6
2020Dec 31, 202034.2×+12.9
2019Dec 31, 201921.3×+12.7
2018Dec 31, 20188.6×+5.4
2017Dec 29, 20173.2×–

More Avalo Therapeutics figures

See a number that looks wrong?